A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
This phase 3 study will evaluate the superiority of the fixed dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag) in participants with unresectable locally advanced or metastatic melanoma. Opdulag is approved in the US for treatment of patients with unresectable or metastatic melanoma.
Principal Investigator: Dr. Jesse Keller
Study Coordinator: Maureen Dempsey and Joe Manacop
This study is currently enrolling patients. To learn more about this study and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through Regeneron
Principal Investigator: Dr. Jesse Keller
Study Coordinator: Maureen Dempsey and Joe Manacop
This study is currently enrolling patients. To learn more about this study and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through Regeneron